The life-sciences company expects its capsules and health business to return to growth in 2025, after sales and earnings fell ...

Jefferies analyst James Vane maintained a Buy rating on Lonza Group Ltd (LONN – Research Report) today and set a price target of ...

Switzerland-based Lonza Group was trading nearly 3% lower by lunchtime Wednesday after presenting its financial results for ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

The Lonza CEO said the company is not under any pressure to exit the Capsules and Health Ingredients (CHI) business and is ...

With the purchase of a former Lonza biologics plant now in the books, San Francisco-based CDMO Joinn Biologics is expanding from one Bay Area to another. | CDMO Joinn Biologics has completed its ...

The recently acquired Genentech facility in Vacaville, California, is expected to generate CHF 0.5 billion in revenue for ...

After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking off 2025 with a return to the dealmaking table. Under a new licensing ...

After revenue boomed for biopharma manufacturers during the COVID pandemic, sales have stagnated for several CDMO giants, ...

UBS analyst Patrick Rafaisz maintained a Buy rating on Lonza Group Ltd (LONN – Research Report) today and set a price target of ...

Approaching his 200th day as the new Chief Executive Officer of Lonza, Wolfgang Wienand discussed the company’s plans to exit the Capsules and Health Ingredients (CHI) business and concentrate ...